Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px
Document › Details

BioMed X GmbH. (10/25/17). "Press Release: BioMed X Announces Biomedical Research Collaboration with Janssen". Heidelberg.

Region Region Heidelberg
  Country Germany
Organisations Organisation BioMed X GmbH
  Organisation 2 Janssen Research & Development LLC
  Group Johnson & Johnson (JnJ) (Group)
Products Product drug discovery
  Product 2 immuno modulatory compound (IMO)
Index term Index term JnJ–BioMed X: pharma research, 201710– collab up to five research projects in area of autoimmune disease w Janssen RnD LLC
Person Person Tidona, Christian (BioRN Cluster Management GmbH 201109 Managing Director)
     


BioMed X announced today a collaboration agreement with Janssen Research & Development, LLC (Janssen) to foster early-stage preclinical biomedical research and development projects. Under the agreement, the BioMed X Innovation Center in Heidelberg, Germany will accommodate up to five Janssen research projects.

The first research project will focus on rapid identification of auto-antigens in autoimmune diseases. Epidemiological data provide evidence of a steady increase in autoimmune diseases worldwide over the last decades. More than 100 different autoimmune diseases have been identified so far, many of them being chronic and life-threatening. New platform technologies or concepts may lead to identification of antigens recognized by T cells involved in autoimmune responses. Talented young scientists from the world’s top universities and research institutions are invited to submit innovative project proposals and apply for a research fellowship at the BioMed X Innovation Center in Heidelberg. Proposed experimental approaches should include the development and validation of novel antigen screening platforms that can rapidly decode the specificities of autoreactive T cells from patient samples. Ideally, the identified T cell epitopes should link back to relevant tissue-specific proteins that are targeted in disease. Screening approaches may incorporate a combination of in vitro, in vivo and in silico (bioinformatics) methods. As part of the project, the novel approach should be validated in a disease context of organ-specific autoimmune diseases, including but not limited to rheumatoid arthritis (RA), type 1 diabetes (T1D), multiple sclerosis (MS), or psoriasis.

“We are very pleased to extend our portfolio of partners with Janssen, an innovative global biopharmaceutical company”, said Christian Tidona, founder and Managing Director of BioMed X. “The new project in the field of autoimmune diseases will benefit from cross-fertilization with our existing expertise and add new capabilities in the field of immunology.”

Details about the call for application can be found on the website of the BioMed X Innovation Center at www.bio.mx.


About BioMed X Innovation Center

The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At the center, distinguished early career scientists recruited from all over the world jointly work on novel pre-clinical research projects in the fields of oncology, immunology, neuroscience, respiratory, diagnostics, consumer care. These interdisciplinary project teams conduct groundbreaking biomedical research in an open innovation lab facility on the campus of the University of Heidelberg, Germany. They are working under the guidance of experienced mentors from academia and industry while expanding their scientific network. Each team is typically sponsored by a corporate partner of BioMed X. After a fully funded project term, successful projects are either internalized into the development pipeline of the respective corporate partner or transformed into an independent start-up company. BioMed X collaborates with global companies such as AbbVie, Boehringer Ingelheim, Merck and Roche Diagnostics.

   
Record changed: 2017-11-30

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for BioMed X GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px